Neuroendocrine Cancer of the Prostate
Autor: | Tamás Kullmann, Károly Kocsis, Noémi Kránitz, Zsolt Szepesváry |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Neuroendocrine Cancer Disease Pathology and Forensic Medicine 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Internal medicine Humans Medicine Aged Chemotherapy business.industry Prostatectomy Incidence Incidence (epidemiology) Prostatic Neoplasms General Medicine Middle Aged medicine.disease Neuroendocrine Tumors 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Immunohistochemistry business |
Zdroj: | Pathology & Oncology Research. 26:1447-1450 |
ISSN: | 1532-2807 1219-4956 |
DOI: | 10.1007/s12253-019-00712-2 |
Popis: | Neuroendocrine cancer of the prostate is considered to be a rare entity with bad prognosis and limited therapeutic options. We performed a prospective analysis of the patients treated in our hospital for prostate cancer between 1st January 2015 and 31rd December 2018. Neuroendocrine phenomena were tested by immunohistochemistry and laboratory chemistry on the request of the clinicians in the cases when a positive diagnosis was suspected. Clinical tableaux of high suspicion of neuroendocrine cancer included radiological progression of a metastatic disease without PSA rise, relatively extended metastatic disease associated to a low PSA, disease with non-pulmonary visceral metastases. 10 patients were diagnosed with neuroendocrine tumour out of 521 prostate cancers. Half of the patients had a survival over a year. 3 patients received 3 lines of efficacious palliative chemotherapy. 1 patient underwent prostatectomy after neoadjuvant chemotherapy for a localised disease. The incidence of neuroendocrine tumours among prostate cancer patients was higher than expected. Some of the patients had a relatively good outcome. |
Databáze: | OpenAIRE |
Externí odkaz: |